Newcastle University

Prof. Hilary Calvert
Head of Academic Department of Medical Oncology

• Email: sandra.cartwright@ncl.ac.uk (personal assistant)
• Telephone: 0191 246 4300
• Fax: 0191 246 4301
• Address: Northern Institute for Cancer Research
  Paul O'Gorman Building
  Medical School
  Framlington Place
  Newcastle upon Tyne
  NE2 4HH
  

Selected Publications

• Lacombe D; Butler-Smith A; Therasse P; Fumoleau P; Burtles S; Calvert AH; Marsoni S; Sessa C; Verweij J. Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network. Cancer Investigation 2003, 21(1), 137-147.
• Parmar MKB; Adams M; Balestrino M; Bertelsen K; Bonazzi C; Calvert AH; Colombo N; Delaloye JF; Durando A; Guthrie D; Hagen B; Harper P; Mangioni C; Perren T; Poole C; Qian W; Rustin G; Sandercock J; Tumolo S; Torri V; Vecchione F. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. The Lancet 2002, 360(9332), 505-515.
• Davies TG; Endicott JA; Noble ME; Johnson LN; Arris CE; Bentley J; Boyle FT; Calvert AH; Curtin NJ; Jewsbury PJ; Gibson AE; Golding BT; Griffin RJ; Hardcastle I; Mesguiche V; Parsons R; Whitfield H; Newell DR. Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design. Cellular and Molecular Biology Letters 2001, 6(2B), 514-515.
• Davies TG; Endicott JA; Johnson LN; Noble ME; Arris CE; Bentley J; Calvert AH; Curtin NJ; Golding BT; Griffin RJ; Hardcastle IH; Mesguiche V; Newell H; Parsons RJ; Whitfield HJ; Boyle T; Jewsbury P. Structure based design of a potent inhibitor of cdk2. Cellular and Molecular Biology Letters 2001, 6(2B), 470.
• Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M; Simmonds D; Cantwell BMJ; Calvert AH. Pharmacokinetics and Pharmacodynamics of Prolonged Oral Etoposide in Women with Metastatic Breast-Cancer. Cancer Chemotherapy and Pharmacology 1995, 37(1-2), 161-167.
• Marsham PR; Jackman AL; Barker AJ; Boyle FT; Pegg SJ; Wardleworth JM; Kimbell R; O'Connor BM; Calvert AH; Hughes LR. Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series. Journal of Medicinal Chemistry 1995, 38(6), 994-1004.

More Publications